Investment Analysts’ Weekly Ratings Changes for United Therapeutics (UTHR)

United Therapeutics (NASDAQ: UTHR) has recently received a number of price target changes and ratings updates:

• 3/5/2026 – United Therapeutics had its price target raised by UBS Group AG from $655.00 to $705.00. They now have a “buy” rating on the stock.
• 3/2/2026 – United Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 2/26/2026 – United Therapeutics had its price target raised by HC Wainwright from $525.00 to $600.00. They now have a “buy” rating on the stock.
• 2/26/2026 – United Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $575.00 to $600.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – United Therapeutics had its price target raised by Royal Bank Of Canada from $587.00 to $643.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – United Therapeutics had its price target raised by Wells Fargo & Company from $423.00 to $466.00. They now have an “equal weight” rating on the stock.
• 2/25/2026 – United Therapeutics had its price target raised by TD Cowen from $525.00 to $575.00. They now have a “buy” rating on the stock.
• 2/25/2026 – United Therapeutics had its “neutral” rating reaffirmed by Bank of America Corporation.
• 2/17/2026 – United Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 1/6/2026 – United Therapeutics had its price target raised by UBS Group AG from $600.00 to $645.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, December 15th. The stock was sold at an average price of $496.30, for a total value of $11,166,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the sale, the chief financial officer directly owned 8,142 shares of the company’s stock, valued at $3,896,761.20. The trade was a 72.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 356,454 shares of company stock valued at $172,894,963 in the last 90 days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.